A Phase 3 clinical trial involving cagrilintide has updated its status as of August 31, 2026. The study, registered as NCT05567796 and titled "A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight," is currently listed as active, not recruiting.
CagriSema is a combination investigational treatment that includes cagrilintide. Cagrilintide itself remains an unapproved compound used only in research settings. This trial update reflects a change in recruitment status rather than any reported results or outcomes.
Active, not recruiting means that participant enrollment for this study has concluded, but the trial itself is ongoing. No efficacy or safety findings have been disclosed as part of this status update. The information available pertains solely to trial progression, not to any conclusions about how the treatment performs.
Details about this study, including its design and objectives, are publicly available through the clinical trial registry. As with all research-stage compounds, cagrilintide's regulatory status remains unapproved for general use outside of clinical research settings.
Readers interested in learning more about cagrilintide's background and research history can consult the compound overview for additional context.